Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05839912 · ClinicalTrials.gov registry record · NA
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
A NA study of Melanoma, sponsored by Craig L Slingluff, Jr.
- Recruiting
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 7
- Study locations
NCT05839912 is a NA study of Melanoma that is actively recruiting participants, run by Craig L Slingluff, Jr. The registered enrollment target is 66 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05839912, a NA study of Melanoma, is actively recruiting participants, sponsored by Craig L Slingluff, Jr.
- RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and how much the surgery impacts quality of life. In order to be eligible for this study, participants must have been diagnosed with metastatic melanoma and have one detected cancerous lymph node by imaging (CT/PET scan) or clinical examination, and are a candidate for lymph node excision.
Conditions Studied
Interventions
- PROCEDURE Excision of clinically detected lymph node metastasis before any systemic therapy
- PROCEDURE Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Study Locations (7)
Georgia
- Emory University - Atlanta
Maryland
- University of Maryland - Baltimore
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Health System - Durham
Pennsylvania
- University of Pennsylvania - Philadelphia
Virginia
- Cancer Center at the University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2028-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05839912
The ClinicalTrials.gov registry entry for NCT05839912 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Excision of clinically detected lymph node metastasis before any systemic therapy is the first listed.
NCT05839912 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Georgia, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT05839912 about?
NCT05839912 is a clinical study titled "Excision of Lymph Node Trial (EXCILYNT) (Mel69)". The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and h...
What is the current status of trial NCT05839912?
This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2023-09-06. Estimated completion is 2028-09-01.
What conditions does trial NCT05839912 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT05839912?
The interventions under investigation include: Excision of clinically detected lymph node metastasis before any systemic therapy (PROCEDURE), Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05839912?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05839912 being conducted?
This trial has 7 study locations across Georgia, Maryland, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
RECRUITING · NA
-
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
RECRUITING · NA
-
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.